A phase II, randomized, double‐blind, placebo‐controlled study evaluating the efficacy and safety of MDX‐1100, a fully human anti‐CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis
Arthritis & Rheumatism2011Vol. 64(6), pp. 1730–1739
Citations Over TimeTop 10% of 2011 papers
Michael Yellin, I.A. Paliienko, Andra Bălănescu, S.Kh. Ter-Vartanian, Vira Tseluyko, Li‐An Xu, Xiaolu Tao, Pina M. Cardarelli, Heidi Leblanc, Geoff Nichol, Codrina Ancuța, Rodica Chirieac, Allison Luo
Abstract
MDX-1100 was well tolerated and demonstrated clinical efficacy in RA patients whose disease responded inadequately to MTX. This is the first study to demonstrate clinical efficacy of a chemokine inhibitor in RA and supports the notion of a potential role of IP-10 in the immunopathogenesis of RA.
Related Papers
- → Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone(2003)70 cited
- Intrarticular methotrexate in the therapy of rheumatoid arthritis.(1989)
- → Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy(2004)8 cited
- → Methotrexate in Treatment of Rheumatoid Arthritis(1999)
- → HSD133 Factors Influencing Selection of First Add-on Disease-Modifying Therapy for Rheumatoid Arthritis after Starting Methotrexate(2022)